Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Summary

People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study. If they fulfill the inclusion and none of the exclusion criteria, they will be, after signing informed consent, randomized to a six-month intervention with either pioglitazone, empagliflozin or semaglutide. Fat biopsies are obtained from the subcutaneous abdominal area before and after a hyperinsulinemic-euglycemic clamp at baseline and after six months. Participants are regularly followed during this the intervention. The overall goal is to determine how antidiabetic-drugs affect white adipose tissue cellularity and whether adipose heterogeneity impacts on drug response. The primary outcome measure is the change in fat tissue lipolysis (glycerol release in isolated fat cells after hormone stimulation) before and after treatment.

Eligibility

Inclusion Criteria:

* Signed informed consent
* BMI 25 kg/m2 or higher
* HbA1c 42 mmol/mol or higher
* For fertile women, effective contraception

Exclusion Criteria:

* HbA1c 65 mmol/mol or higher
* Established cardiovascular disease and/or heart failure
* Severe psychiatric condition
* Active alcoholism
* Insulin treatment
* Anticoagulant therapy (vitamin K antagonists or equivalent)
* Pregnancy, lactation
* Positive GAD or IA2 antibodies
* Low C-peptide/glucose ratio (less than 2 measured as pmol/mg per dL)
* NT-proBNP above the upper normal reference value
* Kidney disease
* Liver disease or hepatic values over twice the upper reference value
* Severe concomitant disease including ongoing cancer

Conditions2

Interventions3

Related trials

• EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus — Medanta, The Medicity, India
• Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia — University Hospital, Basel, Switzerland
• Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease — National Taiwan University Hospital
• To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults — Hyundai Pharm
• SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan — The University of Texas Health Science Center at San Antonio
• SGLT2i, Hepatic Glucose Production, and SNS — The University of Texas Health Science Center at San Antonio
• SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia — The University of Texas Health Science Center at San Antonio

Browse More Trials